Aurora Biosciences Corp., of San Diego, said it received U.S. Patent No. 6,200,762 titled ¿Photon Reducing Agents for Fluorescence Assays.¿ It covers claims to compositions used in cell-based assays, particularly those using fluorescence or luminescence measurements. Aurora also said it received U.S. Patent No. 6,214,563 titled ¿Photon Reducing Agents for Reducing Undesired Light Emission in Assays.¿ It covers use of Aurora¿s enhanced system solution that provides for enhanced assay sensitivity and increased signal to noise ratios for high-throughput screening applications.
Avigen Inc., of Alameda, Calif. said it received U.S. Patent No. 6,211,163. It covers the administration of adeno-associated viral vectors directly into the bloodstream by intravenous injection.
Coley Pharmaceutical Group, of Wellesley, Mass., said it received U.S. Patent No. 6,207,646 titled ¿Immunostimulatory Nucleic Acid Molecules.¿ It covers composition and use claims for CpG immune stimulants.
Dendreon Corp., of Seattle, said it received U.S. Patent No. 6,194,152. It covers a gene displayed in high incidence in a variety of cancers.
Endocare Inc., of Irvine, Calif., said it received U.S. Patent No. 5,531,742 titled ¿Apparatus and Method for Computer Controlled Cryosurgery,¿ by license. It covers a method for computer-controlled cryosurgery.
ImClone Systems Inc., of New York, said it received U.S. Patent No. 6,217,866. It covers the combination of anti-epidermal growth factor receptor monoclonal antibodies and anti-neoplastic agents for use in treatment of cancer.
XOMA Ltd., of Berkeley, Calif., said it received U.S. Patent No. 6,204,023 titled ¿Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use.¿ It covers processes of preparing immunoglobulins secreted from bacteria that are capable of antigen binding.